{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T03:51:42Z","timestamp":1780890702911,"version":"3.54.1"},"reference-count":18,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We report the first case of orbital myeloid sarcoma that was successfully treated with a standard venetoclax dose of 25%. A 38-year-old man with acute myeloid leukemia (AML) post-haplo-hematopoietic stem cell transplantation (HSCT) presented with a nine-month history of progressive right proptosis and a visual acuity deficit. The patient was treated with venetoclax (100\u2005mg orally on days 1\u201328), cytarabine (40\u2005mg subcutaneously, days 1\u201310), and itraconazole (100\u2005mg twice daily orally on days 1\u201328).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>The present case report shows that using cytochrome P450 (CYP) inhibitors is a helpful strategy to reduce the cost of expensive treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>There are limited data on the use of CYP inhibitors as a strategy to reduce the costs of expensive drugs (i.e. venetoclax). This approach has some advantages over standard dose venetoclax (400\u2005mg\/day) such as significantly reduced costs (which is relevant for patients in low-income countries). In this case, we used itraconazole\u2014a potent CYP3A4 inhibitor\u2014which can theoretically reduce the dose to 100\u2005mg\/day without losing serum therapeutic concentrations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221110826","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T02:16:20Z","timestamp":1656036980000},"page":"493-497","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor"],"prefix":"10.1177","volume":"29","author":[{"given":"Fernando","family":"De la Garza-Salazar","sequence":"first","affiliation":[{"name":"Facultad de Medicina y Hospital Universitario \u201cDr Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d Haematology service, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha P","family":"Pe\u00f1a-Lozano","sequence":"additional","affiliation":[{"name":"Facultad de Medicina y Hospital Universitario \u201cDr Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d Haematology service, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"G\u00f3mez-Almaguer","sequence":"additional","affiliation":[{"name":"Facultad de Medicina y Hospital Universitario \u201cDr Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d Haematology service, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-439X","authenticated-orcid":false,"given":"Perla R","family":"Colunga-Pedraza","sequence":"additional","affiliation":[{"name":"Facultad de Medicina y Hospital Universitario \u201cDr Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d Haematology service, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"bibr1-10781552221110826","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.02.027"},{"key":"bibr2-10781552221110826","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2013.06.004"},{"key":"bibr3-10781552221110826","first-page":"1647","volume":"61","author":"Saika W","year":"2020","journal-title":"Rinsho Ketsueki"},{"key":"bibr4-10781552221110826","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0233-1"},{"key":"bibr5-10781552221110826","author":"Koller E","year":"2020","journal-title":"N Engl J Med"},{"key":"bibr6-10781552221110826","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-021-01328-y"},{"key":"bibr7-10781552221110826","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33508"},{"key":"bibr8-10781552221110826","first-page":"1","volume":"06","author":"Zeghondy J","year":"2020","journal-title":"Oncol Cancer Case Reports"},{"key":"bibr9-10781552221110826","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111961"},{"key":"bibr10-10781552221110826","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3028387"},{"key":"bibr11-10781552221110826","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12716"},{"key":"bibr12-10781552221110826","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03907-1"},{"key":"bibr13-10781552221110826","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0612-8"},{"key":"bibr14-10781552221110826","unstructured":"Drugs.com [Internet]. Venclexta Prices, Coupons and Patient Assistance Programs; c1996\u20132022 (cited 07 January 2022)."},{"key":"bibr15-10781552221110826","unstructured":"Farmacias Especializadas FESA [Internet]. Venclexta 42 y 120 tabletas, https:\/\/www.farmaciasespecializadas.com\/medicamentos\/detalle\/29539-venclexta-venetoclax-1050100-mg-tab-caj-c42 (accessed 7 January 2022)."},{"key":"bibr16-10781552221110826","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04168-2"},{"key":"bibr17-10781552221110826","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00753"},{"key":"bibr18-10781552221110826","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1862"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221110826","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221110826","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221110826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:14Z","timestamp":1777688834000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221110826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1177\/10781552221110826"],"URL":"https:\/\/doi.org\/10.1177\/10781552221110826","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]}}}